Alexandra Schneider, Eva Freisinger, Bettina Beck and Bernhard Lippert*

Fachbereich Chemie, Universität Dortmund, D-44227 Dortmund, Germany. E-mail: Lippert@pop.uni-dortmund.de

Received 17th January 2000, Accepted 7th February 2000 Published on the Web 24th February 2000

Mixed-metal (Pt^{II}, Pd^{II}) μ -NH₂-complexes are readily formed upon reaction of trans-[(NH₃)₂PtL₂] (L = 2-amino-pyridine- N^1 or pyrazolate- N^1 ; charges omitted) with [enPd-(H₂O)₂]²⁺.

Amide (NH₂, NHR, NRR') complexes of the late transition metals are, unlike those of the early transition elements and the alkali metal ions, relativly rare.1 Although occasionally suspected intermediates in various catalytic processes such as the Pd catalysed amination of aryl bromides,2 their formation in general requires harsh conditions³ and the absence of water, especially in the case of NH₂ compounds. There are very few crystal structures on NH₂ complexes of Pt available, 4 and there appears to be none for Pd. With alkyl- and aryl-amides the situation is different. Others⁵ and ourselves⁶⁻⁸ have described a series of complexes containing transition metal ions (PtII, PtIV, Hg^{II}) bound to deprotonated exocyclic amino groups of nucleobases. Here we report on mixed-metal (Pt^{II}, Pd^{II}) NH₂ complexes which are formed under mild reaction conditions (room temperature, pH 8–9) in water from trans-[(NH₃)₂PtL₂] (L = pyrazolate, pz, or 2-aminopyridine, Hampy, charges omitted) and $[enPd(H_2O)_2](NO_3)_2$. The role of Pt^{II} is to orient the NH₃ ligands and to acidify the protons, while the N-bonded heterocyclic ligand L provides an additional anchoring group N' for the enPd^{II} entity. The OH ligand of Pd^{II} (average p K_a of $[enPd(H_2O)_2]^{2+}$ ca. 7.8) functions as a base to deprotonate the NH₃ ligand. As we show, the anchoring group N' may be an endocyclic (N2 in pyrazolate) or an exocyclic N-atom (NH2 in 2-aminopyridine).

Starting from trans- $[(NH_2)_2Pt(pz-N^1)_2]1$ † reaction with [enPd- $(H_2O)_2$ ²⁺ and crystallizaton in the presence of Br⁻ yields the trinuclear complex trans-[Pt(μ -NH₂)₂(μ -pz- N^1 , N^2)₂{enPd}₂]-Br₂·2H₂O 2a.‡ În a similar fashion [enPd(H₂O)₂]²⁺ reacts with trans-[Pt(NH₃)₂(Hampy-N¹)₂](NO₃)₂ 3† at the exocylic amino group of the heterocyclic ligand and the NH_3 ligands of Pt^{II} to give trans- $[Pt(\mu-NH_2)_2(ampy-N^1,N^2,N^2')_2\{enPd\}_2Pd(H_2O)]$ -(NO₃)₄·2H₂O 4a.§ We assume that initially the exocyclic amino group of the Hampy ligand is not deprotonated but rather that its deprotonation is the consequence of insertion of an additional trans-square planar Pd^{II} entity between the amino groups of the two aminopyridine ligands, which leads to the tetranuclear PtPd₃ species 4. Formation of the Pd^{II} ion apparently has occurred through loss of the en ligand of enPdII. Compound 4 has been isolated in three different forms (4a-4c), depending on the anions present in solution (Scheme 1).

The X-ray structure determination of 2a¶ proves that the cation is trinuclear and centrosymmetric (Fig. 1). Except for the en ligands, the cation is planar. The geometry of the pz ligands is normal. Comparison of the M–N bond lengths reveals the *trans* influence of the amide group; Pd(1)–N(21) is significantly (6σ) longer than Pd(1)–N(22). The cations in 2a are stacked, in such a way as to form Pd···Pt···Pd of ca. 3.5 Å contacts. Brions and water molecules are arrayed in a honeycomb pattern.

The structure of the cation of trans-[Pt(μ-NH₂)₂(ampy-

DOI: 10.1039/b0004561





Fig. 1 View of the cation of **2a** with atom numbering scheme and section of the crystal packing. Bond lengths (Å): Pd(1)–N(2) 2.001(5), Pd(1)–N(11) 2.011(5), Pt(1)–N(11) 2.044(5), Pt(1)–N(1) 2.010(5), Pt(1)–Pd(1) 3.486(1), Pt(1)–Pd(1d) 3.516(2). Bond angles (°): N(2)–Pd(1)–N(11) 88.4(2), Pd(1)–N(11)–Pt(1) 118.5(2), N(11)–Pt(1)–N(1) 92.0(0).



Scheme 1

 $N^1,N^2,N^2)_2\{{\rm enPd}\}_2{\rm Pd}({\rm H_2O})]({\rm NO_3})_4\cdot 2{\rm H_2O}$ 4a|| (Fig. 2) consists of the four heavy metal ions, two μ -NH₂ groups and two bridging μ -amidopyridine ligands, as well as an aqua and two en ligands. In addition, there is a weak contact between Pt(1) and one of the nitrate anions which effectively leads to a (5 + 1) co-ordination at the Pt atom. The four heavy metals form a slightly irregular but planar diamond (Fig. 2) with only the short diagonal Pt(1)–Pd(1) representing a metal–metal bond. The torsion between the two ampy ligands makes the cation chiral. The cations of trans-[Pt(μ -NH₂)₂(ampy- N^1,N^2,N^2)₂-{enPd}₂PdCl](NO₃)₃·1.3H₂O 4b|| and of trans-[Pt(μ -NH₂)₂




Fig. 2 View of the cation of 4a and schematic disposition of the heavy metals. Bond lengths (Å): Pt(1)-N(1) 2.026(5), Pt(1)-N(1') 2.016(5), Pt(1)–N(11) 2.038(6), Pt(1)–N(11') 2.041(6), Pd(2)–N(11') 2.039(6). Bond angles (°): N(1')-Pt(1)-N(1) 175(2), N(2')-Pd(1)-N(2) 168.0(2).

 $(ampy-N^1,N^2,N^2')_2\{enPd\}_2PdBr]Br(NO_3)_2\cdot 4.6H_2O \ 4c \parallel are \ very$ similar to that of 4a. As expected, 11 distances between Pd(1) and X as well as between Pd(1) and Pt(1) effect each other mutually. There are no unusual bond distances between the metal ions and their N ligands.

Both 2 and 4 display NH₂ resonances at around δ 1–2 (D₂O, pD 7.8). The isotopic exchange of ¹H by ²D of these groups is surprisingly slow (3 d). ${}^{2}J({}^{195}Pt^{-1}H)$ coupling of ca. 45 Hz is observed, as confirmed by an HMQC experiment.

Our findings suggest that it might be possible to develop a similar chemistry with Pt-diam(m)ine compounds of cis geometry and of species with other bridging groups such as hydroxo, methoxo, thiolato or phosphido ligands. The latter are generally obtained *via* substitution of μ-Cl groups by ligands.¹²

Notes and references

 \dagger 1 was synthesised in a way analogous to $3^{\,13}$ from its protonated form followed by treatment with aqueous NH3 to give poorly soluble 1. ‡ To a suspension of 1 (0.2 mmol in 10 mL of H₂O) [enPd-(H₂O)₂](NO₃)₂ (0.4 mmol in 5 mL H₂O) is added. The pH of the mixture is adjusted with 1 M NaOH to 8-9. After 24 h stirring at room temperature slightly green needles of $[Pt(\mu-NH_2)_2(\mu-pz-N^1,N^2)_2-\{enPd\}_2](NO_3)_2\cdot 3H_2O$ **2** are formed, 73 mg, (42%). Anal. Calc. for $C_{10}H_{32}N_{12}O_9Pd_2Pt$: C, 13.8; N, 19.3; H, 3.7. Found: C, 13.8; N, 19.3; H, 3.4%. Crystals suitable for X-ray crystallography of the Br salt 2a were obtained by following recrystallization of 2 from an aqueous solution containing trimethylammonium bromide.

§ A solution of trans-[Pt(NH₃)₂(Hampy)₂](NO₃)₂ 3 (0.2 mmol in 10 mL of H₂O) is combined with [enPd(H₂O)₂](NO₃)₂ (0.8 mmol in 10 mL H₂O) and the pH is adjusted with 1 M NaOH to 8-9. The mixture is stirred for 2 d at room temperature. Upon slow reduction of the volume in a stream of nitrogen dark brown crystals of trans-[Pt(µ-NH₂)₂(ampy- N^1,N^2,N^2' ₂{enPd}₂Pd(H₂O)](NO₃)₄·2H₂O **4a** are formed which are suitable for X-ray analysis, 65 mg (29%). Anal. Calc. for C₁₄H₃₆-N₁₄O₁₅Pd₃Pt: C, 14.6; N, 17.0; H, 3.1. Found: C, 14.4; N, 17.1; H, 3.3%. 4b and 4c are obtained from solutions of 4a in water in the presence of 1 equiv of NaCl and 2 equiv of KBr, respectively.

¶Crystal data of 2a: C₅H₁₅N₅OBrPdPt_{0.5}; triclinic, space group $P\bar{1}$; a = 5.0470(10), b = 9.580(2), c = 13.568(3) Å; a = 105.65(3), $\beta = 105.65(3)$ 98.84(3), $\gamma = 98.60(3)^{\circ}$; V = 611.5(2) Å³; $\rho_{\text{calc}} = 2.417$ g cm⁻³; $2\theta_{\text{max}} = 54.2^{\circ}$; $\mu = 10.452 \text{ mm}^{-1}$; crystal dimensions: $0.56 \times 0.13 \times 0.04 \text{ mm}$, $R_1 = 0.0325$, $wR_2 = 0.0827$. Unique diffractometer data sets were measured at T = 293(2) K (Enraf-Nonius- κ CCD-diffractometer) using MoKα radiation $\lambda = 0.71069$ Å, N = 2464 independent reflections were obtained $N_0 = 2070 \ (I > 2\sigma(I))$ being considered 'observed'; integration and Lp-corrections of the frames were performed using the DENZOpackage. 14 The structures were solved using SHELXS-86 and developed via alternating least squares cycles and Fourier difference synthesies with the aid of the SHELXTL-PLUS programs and SHELXL-93.1 || Crystal data of 4a: C₁₄H₃₆N₁₄O₁₅Pd₃Pt; monoclinic, space group P2₁/ c; a = 8.274(2), b = 13.653(3), c = 27.992(6) Å; $\beta = 92.56(3)^\circ$; V = 3159.0(12) ų; $\rho_{\text{calc}} = 2.428$ g cm³; $2\theta_{\text{max}} = 43.4^\circ$; $\mu = 6.182$ mm¹; crystal dimensions: $0.38 \times 0.13 \times 0.06$ mm, $MoK\alpha$ ($\lambda = 0.71069$ Å); T=136(2) K; N=3631, N_0 =2810 (I>2 $\sigma(I)$); R_1 =0.0248, wR_2 =0.0458. Crystal data of **4b**: $C_{14}H_{32.6}N_{13}O_{10.3}ClPd_3Pt$; triclinic, space group $P\bar{1}$; a=11.046(2), b=12.056(2), c=12.971(3) Å; a=101.93(3), $\beta = 102.74(3), \ \gamma = 112.30(3)^\circ; \ V = 1475.9(5) \ \text{Å}^3; \ \rho_{\text{calc}} = 2.470 \ \text{g cm}^{-3}; \ 2\theta_{\text{max}} = 50.0^\circ; \ \mu = 6.685 \ \text{mm}^{-1}; \ \text{crystal dimensions:} \ 0.88 \times 0.19 \times 0.13$ mm, MoK α ($\lambda = 0.71069$ Å); T = 293(2) K; N = 4835, $N_0 = 2893$ $(I > 2\sigma(I))$; R = 0.0369, $R_W = 0.0597$. Crystal data of 4c: $C_{14}H_{39,2}$ $N_{12}O_{10.6}Br_2Pd_3Pt$; triclinic, space group $P\bar{1}$; a = 11.641(2), b = 11.757(2), c = 14.136(3) Å; a = 111.96(3), $\beta = 105.48(3)$, $\gamma = 100.62(3)^{\circ}$; V = 1639.6(5) Å³; $\rho_{\text{calc}} = 2.470$ g cm⁻³; $2\theta_{\text{max}} = 46.6^{\circ}$, $\mu = 8.374$ mm⁻¹; crystal dimensions: $0.38 \times 0.13 \times 0.13$ mm, MoK α ($\lambda = 0.71069$ Å); T =293(3) K; N = 4217, $N_0 = 2844$ $(I > 2\sigma(I))$; $R_1 = 0.0412$, $wR_2 = 0.0835$. CCDC reference number 186/1844. See http://www.rsc.org/suppdata/ dt/b0/b000456l/ for crystallographic files in .cif format.

- 1 M. D. Fryzuk and C. D. Montgomery, Coord. Chem. Rev., 1989, 95,
- 2 M. S. Driver and J. F. Hartwig, Organometallics, 1997, 16, 5706 and refs. therein; J.-F. Marcoux, S. Wagaw and S. L. Buchwald, J. Org. Chem., 1997, 62, 1568 and refs. therein.
- 3 H. Jacobs, R. Niewa, T. Sichla, A. Tenten and U. Zachwieja, *J. Alloys Compd.*, 1997, **246**, 91 and refs. therein.
- 4 M. Kretschmer and L. Heck, Z. Anorg. Allg. Chem., 1982, 490, 215; N. W. Alcock, P. Bergamini, T. J. Kemp, P. G. Pringle, S. Sostero and O. Traverso, Inorg. Chem., 1991, 30, 1595; S. Park, A. L. Rheingold and D. M. Roundhill, Organometallics, 1991, 10, 615; K. Matsumoto and K. Harashima, Inorg. Chem., 1991, 30, 3032.
- 5 J. Apalahti and K. D. Klika, *Eur. J. Inorg. Chem.*, 1999, 1199. 6 B. Lippert, H. Schöllhorn and U. Thewalt, *J. Am. Chem. Soc.*, 1986, **108**, 6616.
- 7 J. Müller, E. Zangrando, N. Pahlke, E. Freisinger, L. Randaccio and B. Lippert, Chem. Eur. J., 1998, 4, 397; J. Müller, F. Glahé, E. Freisinger and B. Lippert, Inorg. Chem., 1999, 38, 3160.
- 8 F. Zamora, M. Kunsman, M. Sabat and B. Lippert, Inorg. Chem., 1997, **36**, 1583.
- 9 R. B. Martin, in Cisplatin: Chemistry and Biochemistry of a leading Anticancer Drug, B. Lippert (editor), VHCA Zuerich and Wiley-VCH, Weinheim, 1999, p. 183.
- 10 W. Burger and J. Strähle, Z. Anorg. Allg. Chem., 1985, 529, 111.
- 11 M. Krumm, B. Lippert, L. Randaccio and E. Zangrando, J. Am. Chem. Soc., 1991, 113, 5129; M. Krumm, E. Zangrando, L. Randaccio, S. Menzer and B. Lippert, Inorg. Chem., 1993, 32, 700; C. Mealli, F. Pichierri, L. Randaccio, E. Zangrando, M. Krumm, D. Holthenrich and B. Lippert, Inorg. Chem., 1995, 34, 3418.
- 12 M. T. Pinillos, A. Elduque, E. Martin, N. Navarro, F. J. Lahoz, J. A. Lopez and L. A. Oro, Inorg. Chem., 1995, 34, 111.
- 13 H. Rauter, I. Mutikainen, M. Blomberg, C. J. L. Lock, P. Amo-Ochoa, E. Freisinger, L. Randaccio, E. Zangrando, E. Chiarparin
- and B. Lippert, Angew. Chem., Int. Ed. Engl., 1997, 36, 1296.

 14 Z. Otwinowski and W. Minor, DENZO SMN, Methods Enzymol., 1997, 276, 307; G. M. Sheldrick, SHELXS-86, SHELXTL-PLUS, SHELXL-93, University of Göttingen, 1986, 1990, 1993.

Communication b0004561